ArticleJournal of the National Cancer Center2025
The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs.
Xi Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.